Barely Significant
← all excerpts

Real-World Outcomes of First-Line Pembrolizumab-Based Therapy in Advanced Non-Small-Cell Lung Cancer: A Retrospective Single-Center Study

J Clin Med · 2026 · PMC13302034

Europe PMC
1
hedged sentence
0.0530
closest p · 1.1× alpha
0.0530
boldest claim

The sentences

showed a trendp = 0.053so close (0.05 < p ≤ 0.1)
Having three or more metastatic sites showed a trend toward worse OS (HR 2.07, 95% CI 0.99–4.35; p = 0.053), but no covariate reached p < 0.05 in the multivariate model, likely reflecting limited statistical power with 45 patients and 40 events.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.